

Initial Prior Authorization with Quantity Limit

Dry Eye Disease Agents

Products Referenced by this Document

Drugs that are listed in the following table include both brand and generic and all dosage forms and strengths unless otherwise stated. Over-the-counter (OTC) products are not included unless otherwise stated.

Brand Name	Generic Name	Dosage Form
Cequa	cyclosporine	ophthalmic solution
Eysuvis	loteprednol etabonate	ophthalmic suspension 0.25%
Miebo	perfluorohexyloctane	ophthalmic solution
Restasis	cyclosporine	ophthalmic emulsion
Tryptyr	acoltremon	ophthalmic solution
Tyrvaya	varenicline	nasal spray solution
Vevye	cyclosporine	ophthalmic solution
Xiidra	lifitegrast	ophthalmic solution

Indications

FDA-approved Indications

Cequa

Cequa ophthalmic solution is a calcineurin inhibitor immunosuppressant indicated to increase tear production in patients with keratoconjunctivitis sicca (dry eye).

Eysuvis

Eysuvis is a corticosteroid indicated for the short-term (up to two weeks) treatment of the signs and symptoms of dry eye disease.

Miebo

Miebo (perfluorohexyloctane ophthalmic solution) is indicated for the treatment of the signs and symptoms of dry eye disease (DED).

Restasis

Restasis ophthalmic emulsion is indicated to increase tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca. Increased tear production was not seen in patients currently taking topical anti-inflammatory drugs or using punctal plugs.

Tryptyr

Tryptyr is indicated for the treatment of the signs and symptoms of dry eye disease.

Tyrvaya

Tyrvaya (varenicline solution) nasal spray is indicated for the treatment of the signs and symptoms of dry eye disease.

Vevye

Vevye is indicated for the treatment of the signs and symptoms of dry eye disease.

Xiidra

Xiidra (lifitegrast ophthalmic solution) 5% is indicated for the treatment of the signs and symptoms of dry eye disease (DED).

Coverage Criteria

Dry Eye Disease

Authorization may be granted when the requested drug is being prescribed for the treatment of dry eye disease when the following criteria is met:

- The request is for Cequa, Miebo, Restasis, Tryptyr, Tyrvaya, Vevye, or Xiidra.

Short Term Dry Eye Disease

Authorization may be granted when the requested drug is being prescribed for the treatment of dry eye disease when the following criteria is met:

- The request is for Eysuvis AND the following criteria is met:
 - The requested drug is being prescribed for short-term use (up to two weeks).

Continuation of Therapy

Dry Eye Disease

Authorization may be granted when the requested drug is being prescribed for the treatment of dry eye disease when ALL of the following criteria are met:

- The request is for Cequa, Miebo, Restasis, Tryptyr, Tyrvaya, Vevye, or Xiidra.
- The patient achieved or maintained improvement in their signs and symptoms of dry eye disease from baseline (e.g., ocular irritation, redness, mucous discharge, reduced visual function, ocular surface damage, reduced tear production).

Short Term Dry Eye Disease

All patients (including new patients) requesting authorization for continuation of therapy for Eysuvis must meet ALL requirements in the coverage criteria section.

Quantity Limits Apply

Limits do not accumulate together; patient is allowed the maximum limit for each drug and strength.

The duration of 25 days is used for a 30-day fill period and 75 days is used for a 90-day fill period to allow time for refill processing.

The duration of 21 days is used for a 28-day fill period and 63 days is used for an 84-day fill period to allow time for refill processing.

Drug	1 Month Limit	3 Month Limit
Cequa (cyclosporine ophthalmic solution)	60 vials / 25 days	180 vials / 75 days
Miebo (perfluorohexyloctane ophthalmic solution)	1 multi-dose bottle (3 mL) / 25 days	3 multi-dose bottles (9 mL) / 75 days

Drug	1 Month Limit	3 Month Limit
Restasis (cyclosporine ophthalmic emulsion)	60 vials / 25 days	180 vials / 75 days
Restasis Multidose (cyclosporine ophthalmic emulsion)	1 multi-dose bottle (5.5 mL) / 21 days	3 multi-dose bottles (16.5 mL) / 63 days
Tryptyr (acoltremon ophthalmic solution)	60 single-dose vials / 25 days	180 single-dose vials / 75 days
Tyrvaya (varenicline nasal spray solution)	2 nasal spray bottles (8.4 mL) / 25 days	6 nasal spray bottles (25.2 mL) / 75 days
Vevye (cyclosporine ophthalmic solution)	1 multi-dose bottle (2 mL) / 25 days	3 multi-dose bottles (6 mL) / 75 days
Xiidra (lifitegrast ophthalmic solution)	60 containers (1 carton) / 25 days	180 containers (3 cartons) / 75 days

These drugs are for short-term acute use.

Drug	Limit
Eysuvis (loteprednol etabonate ophthalmic suspension 0.25%)	2 bottles (16.6 mL) / 90 days

Duration of Approval (DOA)

- 1955-C:
 - Cequa, Miebo, Restasis, Tryptyr, Tyrvaya, Vevye, Xiidra (Dry eye disease): DOA: 12 months
 - Eysuvis (Short term dry eye disease): DOA: 3 months
- BOG 5484-C
 - Cequa, Miebo, Restasis, Tryptyr, Tyrvaya, Vevye, Xiidra (Dry eye disease): DOA: 12 months (If the request is for Restasis, approve Brand name Restasis)
 - Eysuvis (Short term dry eye disease): DOA: 3 months

References

1. Cequa [package insert]. Cranbury, NJ: Sun Pharmaceutical Industries, Inc.; July 2022.
2. Eysuvis [package insert]. Fort Worth, TX: Alcon Laboratories, Inc.; November 2023.

Reference number(s)
1955-C, 5484-C

3. Miebo [package insert]. Bridgewater, NJ: Bausch & Lomb Americas Inc.; January 2024.
4. Restasis [package insert]. Irvine, CA: Allergan, Inc; September 2024.
5. Restasis Multidose [package insert]. Irvine, CA: Allergan, Inc; September 2024.
6. Tryptyr [package insert]. Fort Worth, TX: Alcon Laboratories, Inc. May 2025.
7. Tyrvaya [package insert]. Princeton, NJ: Oyster Point Pharma, Inc.; September 2024.
8. Vevye [package insert]. Nashville, TN: Harrow Eye, LLC.; November 2023.
9. Xiidra [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; June 2020.
10. Lexicomp Online, AHFS DI (Adult and Pediatric Online. Waltham, MA: UpToDate, Inc.; 2024.
<https://online.lexi.com>. Accessed October 16, 2024.
11. Micromedex® (electronic version). Merative, Ann Arbor, Michigan, USA. Available at:
<https://www.micromedexsolutions.com/> (cited: 10/16/2024).
12. Akpek EK, Amescua G, Farid M, et al. Dry Eye Syndrome Preferred Practice Pattern. Ophthalmology. 2019;126(1):P286-P334.
13. Pharmacy Auditing and Dispensing Job Aid: Billing Other Dosage Forms. Centers for Medicare and Medicaid Services. December 2015.